Title
Computational analysis and prediction of the binding motif and protein interacting partners of the Abl SH3 domain

Permalink
https://escholarship.org/uc/item/598624wh

Journal
PLOS Computational Biology, 2(1)

ISSN
1553-734X

Authors
Hou, T J
Chen, K
McLaughlin, W A
et al.

Publication Date
2006

Peer reviewed
Computational Analysis and Prediction of the Binding Motif and Protein Interacting Partners of the Abl SH3 Domain

Tingjun Hou1,2, Ken Chen1,2, William A. McLaughlin1,2, Benzhuo Lu1,2, Wei Wang1,2*

1 Department of Chemistry and Biochemistry, University of California San Diego, La Jolla, California, United States of America, 2 Center for Theoretical Biological Physics, University of California San Diego, La Jolla, California, United States of America

Protein-protein interactions, particularly weak and transient ones, are often mediated by peptide recognition domains, such as Src Homology 2 and 3 (SH2 and SH3) domains, which bind to specific sequence and structural motifs. It is important but challenging to determine the binding specificity of these domains accurately and to predict their physiological interacting partners. In this study, the interactions between 35 peptide ligands (15 binders and 20 non-binders) and the Abl SH3 domain were analyzed using molecular dynamics simulation and the Molecular Mechanics/Poisson-Boltzmann Solvent Area method. The calculated binding free energies correlated well with the rank order of the binding peptides and clearly distinguished binders from non-binders. Free energy component analysis revealed that the van der Waals interactions dictate the binding strength of peptides, whereas the binding specificity is determined by the electrostatic interaction and the polar contribution of desolvation. The binding motif of the Abl SH3 domain was then determined by a virtual mutagenesis method, which mutates the residue at each position of the template peptide relative to all other 19 amino acids and calculates the binding free energy difference between the template and the mutated peptides using the Molecular Mechanics/Poisson-Boltzmann Solvent Area method. A single position mutation free energy profile was thus established and used as a scoring matrix to search peptides recognized by the Abl SH3 domain in the human genome. Our approach successfully picked ten out of 13 experimentally determined binding partners of the Abl SH3 domain among the top 600 candidates from the 218,540 decapeptides with the PXXP motif in the SWISS-PROT database. We expect that this physical-principle based method can be applied to other protein domains as well.

Introduction

The interactions between protein domains and their peptide ligands play critical roles in signal transduction and many other key biological processes. Because domain-peptide interactions are usually weak and transient, and often depend upon post-translational modification, they tend to be under-represented in high-throughput and computational studies [1], thus highlighting the need to develop new methods to identify these interactions. The Src Homology 3 (SH3) domain is the most abundant modular domain in the human proteome and presents in a wide variety of proteins, such as kinases, lipases, GTPases, and adaptor proteins, to orchestrate diverse cellular processes [2–6]. SH3 domains are 50–70 amino acids long and consist of five β-strands arranged into two sheets packed at right angles. They recognize the proline-rich peptides with the consensus motif PXXP (where P is proline and X is any amino acid) [7, 8] that forms a left-handed poly-proline type II (PPII) helix [9]. Depending on the position of the positive residue in the peptide sequence, the majority of SH3 ligands fall into two classes that bind to the protein in opposite orientations [10]: N-terminal to C-terminal (class I) or C-terminal to N-terminal (class II). Class I peptides typically consist of a core motif of RXLPX#P (where # is usually a hydrophobic residue), whereas the class II peptides contain a core motif of PX#PX. In class I peptides, the proline residues in bold occupy the sites in the hydrophobic pocket that are normally referred as position P3 and P5, while the Arg residue occupies position P8 (the positions are often dubbed as P3, P2, P1, P0, P1, P2, and P3 from N-terminal to C-terminal, namely from R to P, in the motif RXLPX#P [2]). A notable variance of this motif is the one recognized by the Abl SH3 domain, which contains a tyrosine or a large hydrophobic residue at position P3.

The binding specificity of a specific SH3 domain is determined by the flanking residues around the core motif PXXP [10]. Understanding the molecular basis of the specificity for each SH3 domain and identifying the sequence motif it recognizes are crucial to reconstruct the complete protein-protein interaction networks mediated by SH3 domains. Both experimental and computational methods

Citation: Hou T, Chen K, McLaughlin WA, Lu B, Wang W (2006) Computational analysis and prediction of the binding motif and protein interacting partners of the Abl SH3 domain. PLoS Comput Biol 2(1): e1.

Editor: Diana Murray, Cornell University, United States of America

Received August 12, 2005; Accepted December 5, 2005; Published January 27, 2006

DOI: 10.1371/journal.pcbi.0020001

Copyright: © 2006 Hou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abbreviations: MD, molecular dynamics; MM/PBSA, Molecular Mechanics/Poisson-Boltzmann Solvent Area; SD, standard deviation; SH2, Src Homology 2 domain; SH3, Src Homology 3 domain; SPMFEP, single position mutation free energy profile; VM, virtual mutagenesis

* To whom correspondence should be addressed. E-mail: wei-wang@ucsd.edu
Synopsis

One of the central questions of molecular biology is to understand how signals are transduced in the cell. Intracellular signal transduction is mainly achieved through cascades of protein-protein interactions, which are often mediated by peptide-binding modular domains. There are several Src Homology 2 (SH2) and SH3) domains, such as those in human protein Abl, which bind to peptides containing the PXXP motif (where P is proline and X is any amino acid). They generate a position-specific scoring matrix to represent the binding motif of the Abl SH3 domain. Analysis on the binding free energy components suggested insights into how the binding specificity is achieved. Most known protein interacting partners of the Abl SH3 domain were correctly identified using the position-specific scoring matrix, and other potential interacting partners were also suggested.

have been developed to tackle this problem. Peptide library screening is often used to determine the binding motif of a SH3 domain, in which the binding peptides are sequenced and aligned to generate a frequency matrix representing the amino acid preference at each position. Bias may be introduced by not completely sampling all possible peptides, not quantitatively weighting the contribution of peptides to the matrix based on their binding strength and/or not distinguishing peptides bound to the SH3 domain in different binding modes. Computational methods such as Scansite [13], SPOT [14], and VIP [15] have been developed to predict interacting proteins of a domain. The performance of Scansite totally depends on the accuracy of the frequency matrix determined by the peptide library experiments. SPOT is limited by the relatively small number of residue contact pairs between SH3 domains and peptides. The performance of the VIP method can be improved if more conformational sampling is done and more rigorous binding energy prediction method, including the conformational energy change and the desolvation contribution upon peptide binding, is applied.

In this study, we analyzed the binding specificity of the SH3 domain of the human protein Abl. The Molecular Mechanics/Poisson-Boltzmann Solvent Area (MM/PBSA) method [16] was first applied to calculate the binding free energies between the Abl SH3 domains and 35 ten-residue-long peptides (15 binders and 20 non-binders). As a validation of the MM/PBSA method on the domain-peptide system, the calculated binding free energies of the 15 known binders correlated well with the experimental values and the largest correlation coefficient is 0.79, SD = 1.7, respectively. We then analyzed the free energy components to search for the dominant factor that dictates the binding specificity (Table 1). As the favorable electrostatic interaction between the peptide and the SH3 domain $\Delta E_{\text{ele}}$ is canceled by the unfavorable electrostatic contribution to desolvation $\Delta G_{\text{PB}}$, the van der Waals interaction $\Delta E_{\text{vdw}}$ is the most favorable component of the binding free energy. The favorable $\Delta E_{\text{vdw}}$ is mainly from the interactions between the conserved proline residues of the PXXP motif and the hydrophobic surface that is formed by Tyr7, Phe9, Trp36, Tyr52, and Pro49 of the Abl SH3 domain and conserved in almost all SH3 domains. To investigate which energetic factor determines the relative binding affinities of these 15 binders, we compared the correlations between the measured binding free energies and each of the four free energy components, $\Delta E_{\text{ele}}$, $\Delta E_{\text{vdw}}$, $\Delta G_{\text{PB}}$, and $\Delta G_{\text{SA}}$. None of these components shows good correlation with the experimental values and the largest correlation coefficient is only 0.49 for $\Delta E_{\text{ele}}$, which suggests that no individual free energy component dominates the binding specificity. We then analyzed the non-polar ($\Delta E_{\text{vdw}} + \Delta G_{\text{SA}}$) and the electrostatic contribution ($\Delta E_{\text{ele}} + \Delta G_{\text{PB}}$) to the binding free energy. The electrostatic contribution correlates well with the binding free energies ($r = 0.73, SD = 1.6$) while the non-polar contribution does not show any correlation ($r = -0.32, SD = 2.0$). It suggests that the binding preference of these peptides is mainly determined by the electrostatic contribution to binding.

We also found that the conformational change of the peptide upon binding $\Delta E_{\text{conf}}$ was important ($r = 0.54, SD = 1.8$). The sum of $\Delta E_{\text{ele}}$, $\Delta E_{\text{vdw}}$, $\Delta G_{\text{PB}}$, $\Delta G_{\text{SA}}$, and $\Delta E_{\text{conf}}$ correlates well with the binding free energies ($r = 0.79, SD = 1.8$) whereas the sum of the first four terms does not ($r = 0.52$). Our calculations highlight the crucial effect of the change of the conformational energy of peptide to the affinities, which is not always appropriately considered [20, 21]. Inclusion of the conformational entropy $-TAS$ in the free energy calculation only slightly improves the correlation coefficient from 0.79–0.82, which suggests that the conforma-

Results

Molecular Basis of the Binding Specificity of the Abl SH3 Domain

The calculated binding free energies correlate well with the experimental values. We first evaluated the performance of the MM/PBSA method on calculating the binding free energies of the Abl SH3 domain and its peptide ligands (15 binders and 20 non-binders). As shown in Table 1 and Figure 1, the calculated relative binding free energies of the 15 known binders show good correlation with the experimental values (the correlation coefficient $r$ and standard deviation [SD] are 0.82 and 1.7, respectively). We then analyzed the free energy components to search for the dominant factor that dictates the binding specificity (Table 1). As the favorable electrostatic interaction between the peptide and the SH3 domain $\Delta E_{\text{ele}}$ is canceled by the unfavorable electrostatic contribution to desolvation $\Delta G_{\text{PB}}$, the van der Waals interaction $\Delta E_{\text{vdw}}$ is the most favorable component of the binding free energy. The favorable $\Delta E_{\text{vdw}}$ is mainly from the interactions between the conserved proline residues of the PXXP motif and the hydrophobic surface that is formed by Tyr7, Phe9, Trp36, Tyr52, and Pro49 of the Abl SH3 domain and conserved in almost all SH3 domains. To investigate which energetic factor determines the relative binding affinities of these 15 binders, we compared the correlations between the measured binding free energies and each of the four free energy components, $\Delta E_{\text{ele}}$, $\Delta E_{\text{vdw}}$, $\Delta G_{\text{PB}}$, and $\Delta G_{\text{SA}}$. None of these components shows good correlation with the experimental values and the largest correlation coefficient is only 0.49 for $\Delta E_{\text{ele}}$, which suggests that no individual free energy component dominates the binding specificity. We then analyzed the non-polar ($\Delta E_{\text{vdw}} + \Delta G_{\text{SA}}$) and the electrostatic contribution ($\Delta E_{\text{ele}} + \Delta G_{\text{PB}}$) to the binding free energy. The electrostatic contribution correlates well with the binding free energies ($r = 0.73, SD = 1.6$) while the non-polar contribution does not show any correlation ($r = -0.32, SD = 2.0$). It suggests that the binding preference of these peptides is mainly determined by the electrostatic contribution to binding.

We also found that the conformational change of the peptide upon binding $\Delta E_{\text{conf}}$ was important ($r = 0.54, SD = 1.8$). The sum of $\Delta E_{\text{ele}}$, $\Delta E_{\text{vdw}}$, $\Delta G_{\text{PB}}$, $\Delta G_{\text{SA}}$, and $\Delta E_{\text{conf}}$ correlates well with the binding free energies ($r = 0.79, SD = 1.8$) whereas the sum of the first four terms does not ($r = 0.52$). Our calculations highlight the crucial effect of the change of the conformational energy of peptide to the affinities, which is not always appropriately considered [20, 21]. Inclusion of the conformational entropy $-TAS$ in the free energy calculation only slightly improves the correlation coefficient from 0.79–0.82, which suggests that the conforma-
Table 1. Energetic Components and Binding Affinities for the 15 Peptide Ligands of the Abl SH3 Domain (kcal/mol)

| Number | Sequence     | ΔGexp | ΔGpred | AEpl | AEvdw | ΔGSA | ΔGBP | TASS | $G_{lig, bound}$ | $G_{lig, unbound}$ | ΔGpred | ΔGpred |
|--------|--------------|-------|--------|------|-------|------|------|------|-----------------|------------------|---------|---------|
| A1     | APSYSPPPP    | -7.94 | 0.00   | -92  | -49.6 | 0.4  | -5.3 | 0.0  | 112.5 ± 2.9     | -31.2 ± 0.2      | -17.8 ± 0.6 | -18.3 ± 1.5 |
| A2     | APTMPPPLPP   | -6.17 | 1.77   | -71  | -49.5 | 0.4  | -5.4 | 0.1  | 112.7 ± 5.1     | -33.6 ± 0.3      | -33.2 ± 0.8 | -36.2 ± 0.9 |
| A3     | PPAAPPPPPPVP | -7.23 | 0.71   | -83  | -50.8 | 0.5  | -5.4 | 0.0  | 101.5 ± 2.6     | -31.8 ± 0.1      | 85.5 ± 0.7   | 83.9 ± 0.3 |
| A4     | FGTPPPPLPP   | -7.03 | 0.91   | -70  | -49.9 | 0.2  | -5.6 | 0.0  | 89.7 ± 7.6      | -33.0 ± 0.3      | -41.8 ± 0.4 | -42.2 ± 1.3 |
| A5     | SPYSPPPP     | -7.83 | 0.11   | -100 | -48.2 | 1.0  | -5.2 | 0.0  | 119.4 ± 2.8     | -31.9 ± 0.1      | -43.6 ± 1.1 | -43.0 ± 0.9 |
| A6     | APTYSPPPP    | -8.72 | 0.72   | -103 | -50.2 | 1.6  | -5.4 | 0.1  | 122.0 ± 16.4    | -31.1 ± 0.4      | -53.9 ± 1.7  | -55.7 ± 0.8 |
| A7     | APTMSPPPLL   | -6.37 | 1.57   | -80  | -50.6 | 0.8  | -5.3 | 0.0  | 103.5 ± 9.0     | -33.8 ± 0.3      | -63.9 ± 2.9  | -64.7 ± 2.6 |
| A8     | APTYPPPLNP   | -5.48 | 2.46   | -97  | -51.3 | 0.5  | -5.5 | 0.0  | 118.7 ± 6.7     | -31.6 ± 0.4      | -90.4 ± 1.6  | -95.2 ± 0.1 |
| A9     | APTYHTPPLL   | -5.30 | 2.64   | -75  | -51.2 | 0.5  | -5.4 | 0.0  | 99.4 ± 1.5      | -30.9 ± 0.1      | -28.3 ± 2.2  | -32.7 ± 1.4 |
| A10    | APTMPPPLPP   | -6.95 | 0.99   | -80  | -48.9 | 0.6  | -5.3 | 0.0  | 99.6 ± 4.9      | -33.4 ± 0.4      | -33.8 ± 1.6  | -34.1 ± 0.2 |
| A11    | APTYPPPLPH   | -6.23 | 1.71   | -83  | -53.6 | 0.7  | -5.7 | 0.0  | 107.4 ± 3.6     | -32.0 ± 0.2      | -39.7 ± 3.6  | -45.3 ± 0.9 |
| A12    | APTYPPPLPL   | -6.17 | 1.77   | -87  | -51.8 | 0.4  | -5.5 | 0.1  | 112.2 ± 6.2     | -31.3 ± 0.4      | -62.3 ± 2.1  | -65.8 ± 0.3 |
| A13    | APTYPPPMPP   | -7.36 | 0.58   | -93  | -50.2 | 0.5  | -5.3 | 0.1  | 113.4 ± 6.9     | -31.4 ± 0.2      | -31.8 ± 0.9  | -31.8 ± 1.3 |
| A14    | APTYSSPLPP   | -7.23 | 0.71   | -90  | -51.2 | 0.3  | -5.5 | 0.1  | 112.2 ± 9.6     | -32.2 ± 0.0      | -56.7 ± 1.2  | -59.5 ± 1.1 |
| A15    | ALPYPPPLPP   | -5.93 | 2.01   | -95  | -45.1 | 0.7  | -5.1 | 0.0  | 116.5 ± 1.8     | -32.9 ± 0.4      | 24.3 ± 0.9   | 24.9 ± 1.8 |

ΔΔGexp is the difference between the experimental binding free energies of each peptide and the template peptide APSYSPPPP. ΔAEpl and ΔAEvdw are the electrostatic interaction and van der Waals interaction between the peptide and the Abl SH3 domain, respectively; ΔGSA and ΔGBP are the non-polar and polar contributions of the solvation free energy upon peptide binding, respectively; $G_{lig, bound}$ and $G_{lig, unbound}$ are the conformational energy of peptide in the bound and un-bound states, respectively, ΔGpred is the predicted binding free energy. ΔΔGpred is the difference between the predicted binding free energy of each peptide and the template peptide APSYSPPPP.

*Standard deviations are estimated from three block average values.

DOI: 10.1371/journal.pcbi.0020001.s001

The binding free energies and the free energy components for the 20 non-binders of the Abl SH3 domain were also calculated (Table S1). Two distributions of the binding free energies for binders and non-binders are distinct (Figure 2), which indicates that the MM/PBSA method can distinguish binders from non-binders. We also found that most non-binders preferred unbound conformations. First, the average conformational entropy change upon binding $-\Delta TASS$ for binders and non-binders are 32.1 kcal/mol and 35.9 kcal/mol, respectively, indicating that most non-binders lost more entropy upon binding than did binders. Second, the change of conformational energy for binders and non-binders are also significantly different: the average value for binders and non-binders are 2.0 kcal/mol and 4.3 kcal/mol, respectively.

The binding motif can be revealed by the VM method. To understand the mechanism of the binding specificity, we need to determine the binding motif of the domain. We analyzed the amino acid preference at each position of the peptide using the VM method (see Materials and Methods). We compared our results with the available experimental measurements at positions P$_3$, P$_0$, P$_{-3}$, and P$_{-5}$ (Tables S3–S6) [17, 22]. These four positions are particularly important for the peptide binding: the two usually conserved Pro residues at P$_3$ and P$_0$ ensure strong binding affinity and

Figure 1. The Correlations between Experimental and Predicted Relative Binding Free Energies of the 15 Binders of the Abl SH3 Domain
DOI: 10.1371/journal.pcbi.0020001.g001

Figure 2. The Distributions of the Predicted Binding Free Energies for Binders and Non-Binders of the Abl SH3 Domain
DOI: 10.1371/journal.pcbi.0020001.g002
residues at P$_{-3}$ and P$_{-5}$ are essential to the binding specificity [9, 10]. To determine the residues of the Abl SH3 domain that are important for peptide binding, the contribution of each SH3 domain residue to binding with the template peptide APSYSPPPPP (the two conserved Pro residues are in bold) was analyzed (the polar contribution to desolvation was calculated using the GB/SA method implemented in the mm$_{-}$pbsa module of AMBER 8 for the sake of efficiency.) (Table S7) [19].

In the crystal structure of APSYSPPPPP complexed with the Abl SH3 domain, the residue at position P$_{-5}$ in the peptide occupies a hydrophobic pocket of the SH3 domain. Proline at this position has relatively strong van der Waals interactions with Trp36 ($-1.3$ kcal/mol) and Trp47 ($-0.9$ kcal/mol) in the Abl SH3 domain (Table S7). Several other residues, Asn, Leu, Met, Phe, Tyr, and Val, are also strongly favored at this position (Figure 3A). It is worth pointing out that the mutation of Pro to Tyr or Phe, does not significantly impair the van der Waals interaction between the peptide and the SH3 domain due to the conformational change of the peptide backbone. Our predicted preference based on free energy calculations is consistent with the experimental results: Pro is the most preferred, whereas other residues especially hydrophobic ones (Phe, Leu, Met, Val, and Trp) are also favored [22].

It should be noted that the preference of residue at P$_{-5}$ are closely related to the residues at the adjacent positions. For example, the known binder FGTYPPPLPP (A4 in Table 1) has a Gly at P$_{-5}$, which is not favored at this position based on the VM result. By analyzing the MD trajectory on A4-SH3 complex, we found that Phe at P$_{-6}$ in A4 can occupy the binding pocket that is occupied by Pro at P$_{-5}$ in the template peptide APSYSPPPPP to form favorable van der Waals interactions with Trp36 and Trp47. Moreover, the benzyl ring of Phe at P$_{-6}$ is parallel to the aromatic ring of Trp47 to form strong π-π stacking interactions. Therefore, if there is a small residue (Ala, Gly, or Ser) at P$_{-5}$, an aromatic residue (Tyr, Phe, or Trp) may be preferred at P$_{-6}$. This suggests that the repertoire of SH3 domain-binding peptides may be much larger than previously thought.

Our analysis showed that Trp, Phe, Tyr, Met, and Pro are favored at P$_{-3}$ (Figure 3B), which is in good agreement with the study of Villanueva’s et al. that the most favorable residues are Trp, Tyr, Phe, and Met (ordered based on the binding free energies) [22]. This observation is consistent with findings that an aromatic residue is favored at P$_{-3}$ of mouse 3BP1, a known binder of the Abl SH3 domain [12, 23, 24]. The energy component analysis (Table S4) suggests that the strong preference of these four residues at this position is mainly due to the favorable non-polar contribution ($\Delta E_{vdw} + \Delta G_{SA}$) upon peptide binding: $\Delta E_{vdw} + \Delta G_{SA}$ for Trp, Tyr, Met, and Phe are $-55.9$, $-55.4$, $-54.4$, and $-53.8$ kcal/mol, respectively, which are stronger than the other 16 residues at this position. Interestingly, positive charged residues, Arg and Lys, are not favored at this position, which is in contrast to most SH3 domain-binding peptides. To investigate the reason, we have compared the electrostatic surfaces of four SH3 domains, Abl tyrosine kinase SH3 domain (PDB entry 1bbz) [25], c-Crk N-terminal SH3 domain (PDB entry 1cka) [26], Grb2 N-terminal SH3 domain (PDB entry 1gbq) [27], and rat amphiphysin-2 SH3 domain (PDB entry 1bb9) [28] (Figure 4). Electrostatic potentials were calculated by solving the Poisson-Boltzmann equation using the Delphi program [29] in Insight II [30]. We find that the rat amphiphysin-2 SH3 domain has the largest areas of negative electrostatic potentials, which is mainly due to the acidic residues in Arg-Thr and extended n-Src loops of the domain. The large patch of negative electrostatic potential explains why the
amphiphysin SH3 domain specifically recognizes the PXRPXR motif with two positively charged Arg residues. The c-Crk N-terminal and the Grb2 N-terminal SH3 domain have distinct but relatively small negative potential near the Arg-Thr and n-Src loop, which may explain why these two SH3 domains bind to peptides only possessing a single positively charged residue. Compared with the other three SH3 domains, the Abl SH3 domain does not possess remarkable and continuous distribution of the negative electrostatic potentials and therefore positively charged residues are not strongly preferred.

Proline is highly preferred at positions P0 and P3. We find that Pro at P0 has favorable interactions with Phe9 and Tyr52 (−1.0 kcal/mol and −1.0 kcal/mol) (Table S7), as well as favorable van der Waals interaction with Pro49 (−0.8 kcal/mol). Experimental and theoretical studies have focused on understanding how SH3 domains recognize the core motif PXXP [31, 32]. Proline is the most favorable residue at this position based on our free energy calculation (Figure 3C). When only the non-polar contribution (ΔE_{ele} + ΔG_{SA}) is considered, the peptide with Pro has the strongest interaction with SH3 (−54.8 kcal/mol) (Table S5), which agrees with the study of Wang et al. [31]. In addition to the non-polar contribution, we found the less unfavorable desolvation-free energy is also an important factor for the preference of proline. For example, the residues at P0 in peptides 16, 19, and 20 (Table S5) all have relatively small side chains (Thr, Val, and Pro, respectively) and have similar protein-ligand electrostatic interactions ΔE_{ele}. When the polar contributions of desolvation-free energies ΔG_{PB} were considered, the peptide 20 has the least unfavorable contribution (ΔE_{ele} + ΔG_{PB} = +25.4 kcal/mol). We believe that upon peptide binding the desolvation cost for the nitrogen-substituted atom in Pro may be less than that of the non-substituted nitrogen atom in the other amino acids, because the non-substituted nitrogen atom can be easily polarized by the solvent [32].

Proline is also strongly selected at P3 in almost all SH3 domain-binding peptides. From the calculated binding free energies (Figure 3D), it is interesting to find that, although Pro is preferred at this position by the Abl SH3 domain, the preference is not very strong. Proline at this position can be mutated to several other residues including Trp, Phe, Met, His, Leu, Glu, and Tyr, and the mutated peptides still have relatively strong binding free energies. Our calculation seems to contrast with what has been suggested about the critical role of Pro at P3 in SH3 ligands [10]. However, in the mutation experiments reported by Pisabarro et al. [17], Pro at P3 in peptide APTYPPPPLPP was mutated to His, Leu, and Tyr, and the binding affinities of the mutated peptides were only slightly decreased from −7.1 kcal/mol to −6.2, −6.2, and −6.2 kcal/mol, respectively. These three favorable residues reported by Pisabarro et al. were also relatively favored in our predictions.

Identifying Physiological Interacting Partners of the Abl SH3 Domain

Based on the comparison between the experimental and calculated results, we have shown that the VM method can determine the binding motif of the Abl SH3 domain. The difference between the binding free energies of the mutated peptide at each position and the template peptide APSYSPPP, called SPMFEP, can be used as a position specific scoring matrix to predict the binding affinities of peptides (Table 2). To evaluate the performance of SPMFEP, the 15 binders and 20 non-binders were first scored using SPMFEP. Two obvious distributions for binders and non-binders can be observed (Figure 5), indicating that binders and non-binders can be successfully distinguished by SPMFEP. The binding affinity of peptide A4 was under-estimated. From our analysis (see above), we know that Phe at P−6 in the peptide A4 is favorable in the hydrophobic binding pocket that is originally occupied by Pro at P−5 in the template peptide. Consequently, the residues at P−6 and P−5 may interact with each other. In SPMFEP, the inter-dependence between positions is not considered. In fact, all methods using a position specific scoring matrix, such as Scansite [13], have the same limitations. Overall, SPMFEP performs well on the selected 35 peptides.

We next scanned the SWISS-PROT using SPMFEP to predict interacting partners of the Abl SH3 domain. There are about 6.2 × 107 ten-residue-long peptides in the current SWISS-PROT database (May 2005), in which about 218,540 ten-residue-long peptides have the PXRPXR motif. Only about 2,600 peptides have scores smaller than two, which are in the top 0.005% (the top 600 peptide sequences in 333 unique human proteins are listed in Table S9). We first carefully examined the top ten candidates in the human proteome (Table 3), among which WASF1 and EVL are known...
Finding the binding partners of the Abl SH3 domain [33, 34]. WASF4 is a homolog of WASF1 and is in the same protein family. SEM6A is a homolog of the mouse protein SEM6D, a known Abl SH3 domain-binding protein, and is therefore likely to be a true binder [35]. In total, we have identified two known binders and two candidates highly supported by experimental evidence, among the top ten peptides, which is a surprisingly good result. As a comparison, the top ten human peptides in the Scansite search are [13] 3BP2, RX, RBMG, TACT, PRL3, SCA3, AT19, AD08, DYN2, and SEP4, among which only 3BP2, the homology of a known binder (mouse protein 3BP2), is likely to be a true binder [36] but no binding information is found for all other candidates in BIND [36] and MINT [37] databases to interact with Abl protein or the Abl SH3 domain. If only considering the top ten candidates, the SPMFEP method based on VM performs better than Scansite on identifying the interacting partners of the Abl SH3 domain.

In MINT [37] and BIND [36], 44 non-redundant proteins have been identified to directly interact with the protein Abl, and 13 of them, including five mouse proteins and eight human proteins, bind to the Abl SH3 domain. We compared the performance of SPMFEP, Scansite [13], and iSPOT [14], to identify these 13 proteins (Table 4). The top 600 candidates found in human proteins and the top 2,000 candidates found in all proteins were saved for further analyses.

SPMFEP can successfully identify ten known binders: seven of the eight human proteins and three of the five mouse proteins (Table 4 and Table S8). 3BP1_mouse and 3BP2_mouse are not ranked highly, considering all proteins (1,593 and 1,895) but they are in the top 500 if only mouse proteins are considered. The human homologues of 3BP1_mouse and 3BP2_mouse are in the top 600 candidates (249 for 3BP1_human and 502 for 3BP2_human) (Table S9) and it is reasonable to believe that they are true binders of the Abl SH3 domain. Overall, we have successfully identified most of the known binders of the Abl SH3 domain.

Scansite can identify eight known binders of the Abl SH3 domain (Table 4). P73_human, not identified by SPMFEP, is ranked 321 in the Scansite result. Agami et al. [38] reported that a P73 mutant P338A could not form stable P73-Abl complexes. If P73 interacts with Abl by ten-residue-long peptide segment, this peptide segment should be AFKQSP-PAVP, which is the same as the peptide identified by Scansite. Based on our VM analysis and mutation experiments by Pisabarro and Serrano [17], Phe at P_5 and Lys at P_4 are not favored. Because Scansite considers 15-residue-long peptides rather than ten-residue-long peptides in SPMFEP, it is likely that the five additional residues may contribute favorably to binding. It is not surprising that the longer the peptide, the more specific, but less sensitive, are the predictions.

Using iSPOT, we can only correctly identify five binders (Table 4). In iSPOT, the scoring matrix was derived from position-specific contacts based on six SH3-peptide or SH3-protein complex structures [14]. The accuracy of the matrix is limited by the relatively small number of residue-resident contacts found between SH3 domains and their binding peptides to fill the 27 × 10 × 10 × 10 position-specific contact matrix.

CABL2_human and SEM6D_mouse (Table 4) cannot be identified by all the three methods. Experiments [35, 39] have shown that their interactions with Abl are mediated by the interaction between the proline-rich region and the Abl SH3 domain. Since the scoring matrix used by all the three methods does not consider dependence between positions, we suspect that synergistic interactions may exist between positions within or beyond the proline-rich regions of the two proteins.

Discussion

In this study, we have demonstrated that the MM/PBSA method can accurately calculate the binding free energies between the Abl SH3 domain and its peptide ligands.

Table 2. SPMFEPs of the Abl SH3 Domain

| Residue | Position |
|---------|----------|
|         | P_6 | P_5 | P_4 | P_3 | P_2 | P_1 | P_0 | P_1 | P_2 | P_3 |
| A       | 0.0  | 6.4 | 0.0 | 6.7 | 0.0 | 5.4 | 6.3 | -0.4 | 2.6 | 1.8 |
| R       | 4.0  | 7.4 | 13.6 | 9.1 | 3.5 | 7.4 | 17.2 | 8.6 | 8.8 | 15.0 |
| N       | 2.0  | 2.9 | 1.4 | 2.3 | 0.8 | 5.2 | 6.2 | 6.6 | 5.0 | 3.3 |
| D       | 4.0  | 20.9 | 4.2 | 16.4 | 12.3 | 18.8 | 11.4 | -0.5 | 2.3 | 15.0 |
| C       | 0.0  | 4.4 | -0.4 | 1.6 | -0.5 | 3.4 | 6.3 | -0.1 | 1.9 | 3.5 |
| Q       | 0.0  | 18.4 | 0.7 | 3.3 | 13.6 | 2.8 | 11.3 | 1.2 | 1.3 | 1.3 |
| E       | 4.0  | 20.7 | 8.6 | 12.0 | 13.7 | 27.1 | 14.2 | 6.6 | 6.6 | 10.7 |
| G       | 0.0  | 9.3 | 0.2 | 3.3 | 0.6 | 7.7 | 6.2 | 0.9 | 6.6 | 11.6 |
| H       | 0.0  | 10.7 | 1.1 | 3.3 | 0.7 | 5.2 | 4.0 | 1.9 | 6.5 | 1.4 |
| I       | 0.0  | 10.8 | 1.1 | 1.5 | 4.3 | 6.2 | 6.9 | 5.4 | 0.3 | 5.5 |
| L       | 0.0  | 3.5 | 1.6 | 1.5 | 7.6 | 6.1 | 7.5 | 1.0 | 1.4 | 3.0 |
| K       | 4.0  | 5.3 | 11.4 | 9.1 | 8.1 | 5.6 | 21.0 | 8.6 | 13.7 | 15.2 |
| M       | 0.0  | 3.3 | 3.3 | 0.3 | 3.1 | 6.4 | 4.0 | 3.8 | 0.8 | 0.5 |
| F       | 0.0  | 3.3 | 2.7 | -1.5 | 8.6 | 7.3 | 7.6 | 5.4 | 0.8 | 0.7 |
| S       | 0.0  | 8.8 | 1.1 | 5.0 | 0.1 | -3.3 | 9.4 | -1.5 | 5.3 | 6.5 |
| T       | 0.0  | 5.2 | -0.2 | 3.5 | -0.9 | 7.5 | 4.6 | 1.0 | 2.3 | 5.2 |
| W       | 0.0  | 13.6 | 0.1 | -2.1 | 7.4 | 3.6 | 1.4 | 1.9 | 1.6 | 1.6 |
| Y       | 0.0  | 3.4 | 4.0 | 0.0 | 3.4 | -2.4 | 5.8 | 4.0 | 1.4 | 2.5 |
| V       | 0.0  | 2.0 | 0.5 | 3.3 | 2.4 | -2.8 | 8.5 | -0.2 | 1.7 | 3.8 |
| P       | 0.0  | 0.0 | -0.6 | 0.9 | -0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |

*Given the conformational flexibility of the terminal residue at P_6, heuristic penalty scores were assigned: 4.0 to the most unfavorable residues R, D, E, K at P_6, 2.0 to N, and 0 to other residues.

DOI: 10.1371/journal.pcbi.0020001.t002

Figure 5. The Distribution of the Predicted Binding Free Energies Based on SPMFEP for Binders and Non-Binders
DOI: 10.1371/journal.pcbi.0020001.g005
Examination of each component of the binding free energy shows that, besides the non-bonded interactions and desolvation effect, the change of the conformational energies of the peptides upon binding is also crucial to determine the binding specificity of the domain. These results are encouraging to apply MD simulation and free energy calculation to understand the molecular mechanism of other domain-peptide and protein-protein interactions.

We have also shown that the VM method can precisely determine the sequence motif recognized by the Abl SH3 domain. The experimental scheme of the VM method is totally different from those of the current peptide library experiments in the following ways: 1) produce all possible peptides that are one amino acid different from the template peptide; (2) measure the “binding” affinities of all these peptides; and, (3) generate a scoring matrix based on the binding affinity differences between the mutated and the template peptides to determine the binding motif.

There are advantages of this scheme. First, the preference of an amino acid is quantitatively measured, based on the binding affinity of the peptide, which at least partially overcomes the sampling difficulty in the current peptide library experiment. Ideally, to determine the binding motif of a domain, one should examine the binding between the domain and all possible peptides of a given length, and align all binding peptides to calculate the frequency of each amino acid occurring at each position. In reality, there are usually only $10^7 - 10^{10}$ peptides in the library, due to the limit of time and cost. If the length of the binding peptide is ten, there are $10^{15} - 10^{18}$ possible peptides and the coverage of the peptide sequence space by the peptide library is about $10^{-6} - 10^{-9}$. If 15-residue-long peptides are considered as in Scansite, the coverage drops dramatically to $10^{-12} - 10^{-9}$. By measuring the relative preference of every amino acid based on the peptide-binding affinities, one overcomes this insufficient sampling issue and mimics the ideal procedure given the position-independence assumption. Second, the VM method can evaluate the penalties of unfavorable amino acids even the peptide do not really bind to the protein, which is very hard if not impossible in the experimental approaches. Third, since the scoring matrix is obtained by taking the difference between the template and the mutated peptides that are only one amino acid different from the template peptide, some

**Table 3. Top Ten Binding Partner Candidates of the Abl SH3 Domain Identified by SPMFEP**

| Rank | Protein | Accession ID | Start | End | Peptide | Score | Scansite Rank | iSPOT Rank | Protein Description |
|------|---------|-------------|-------|-----|---------|-------|---------------|------------|---------------------|
| 1    | RW1     | Q92545      | 1521  | 1530| SPPTPASPPPP | -4.1  | ×             | b          | RW1 protein (fragment) |
| 2    | WASF4   | Q81990      | 475   | 484 | PPEPSPSSFE | -3.6  | ×             | b          | Wiskott-Aldrich syndrome protein family member 4 |
| 3    | TREX1   | Q9NSU2      | 107   | 116 | GPPTVPVPPPP | -3.4  | 1,194        |            | Three prime repair exonuclease 1 |
| 4    | ACRO    | P10323      | 344   | 353 | PPPPSPSPPP | -3.2  | 54           |            | Acrosin [precur sor] |
| 5    | LRNR5   | O73235      | 22    | 31  | VVVPWVPCPP | -2.9  | ×             | b          | Leucine-rich repeats neuronal protein 5 [precur sor] |
| 6    | SEM6A   | Q9H266      | 791   | 800 | MPPMSGVPV  | -2.9  | ×             | b          | Semaphorin 6A [precur sor] |
| 7    | HDAC4   | P56524      | 343   | 352 | LPLYTSPS   | -2.8  | ×             | b          | Histone deacetylase 4 |
| 8    | EVL     | Q9U08       | 185   | 194 | PPPPPVPPPP | -2.7  | 83           |            | Ena/vasodilator stimulated phosphoprotein-like protein |
| 9    | WASF1   | Q92585      | 347   | 356 | TPPPVPVPPP | -2.7  | 132          |            | Wiskott-Aldrich syndrome protein family member 1 |
| 10   | YLPM1   | P49750      | 14    | 23  | YPPPPVVPPP | -2.7  | 115          |            | YLP motif containing protein 1 |

*Only the top 2,000 candidate peptides are shown in the Scansite Web site.

Examination of each component of the binding free energy shows that, besides the non-bonded interactions and desolvation effect, the change of the conformational energies of the peptides upon binding is also crucial to determine the binding specificity of the domain. These results are encouraging to apply MD simulation and free energy calculation to understand the molecular mechanism of other domain-peptide and protein-protein interactions.

We have also shown that the VM method can precisely determine the sequence motif recognized by the Abl SH3 domain. The experimental scheme of the VM method is totally different from those of the current peptide library experiments in the following ways: 1) produce all possible peptides that are one amino acid different from the template peptide; (2) measure the “binding” affinities of all these peptides; and, (3) generate a scoring matrix based on the binding affinity differences between the mutated and the template peptides to determine the binding motif.

There are advantages of this scheme. First, the preference of an amino acid is quantitatively measured, based on the binding affinity of the peptide, which at least partially overcomes the sampling difficulty in the current peptide library experiment. Ideally, to determine the binding motif of a domain, one should examine the binding between the domain and all possible peptides of a given length, and align all binding peptides to calculate the frequency of each amino acid occurring at each position. In reality, there are usually only $10^7 - 10^{10}$ peptides in the library, due to the limit of time and cost. If the length of the binding peptide is ten, there are $10^{15} - 10^{18}$ possible peptides and the coverage of the peptide sequence space by the peptide library is about $10^{-6} - 10^{-9}$. If 15-residue-long peptides are considered as in Scansite, the coverage drops dramatically to $10^{-12} - 10^{-9}$. By measuring the relative preference of every amino acid based on the peptide-binding affinities, one overcomes this insufficient sampling issue and mimics the ideal procedure given the position-independence assumption. Second, the VM method can evaluate the penalties of unfavorable amino acids even the peptide do not really bind to the protein, which is very hard if not impossible in the experimental approaches. Third, since the scoring matrix is obtained by taking the difference between the template and the mutated peptides that are only one amino acid different from the template peptide, some

**Table 4. Comparison of Predictions of SPMFEP, Scansite, and iSPOT on 13 Known Interacting Proteins of the Abl SH3 Domain**

| Protein       | Accession ID | SPMFEP | Scansite | iSPOT | Description                        |
|---------------|--------------|--------|----------|-------|------------------------------------|
| 3BP1_mouse    | P55194       | ✓       | ✓        | ✗     | SH3 domain-binding protein 1       |
| PDE4D2_mouse  | Q80499       | ✓       | ✓        | ✓     | SH3 domain-binding protein 2       |
| EVL_human     | Q9U08        | ✓       | ✓        | ✓     | Ena/vasodilator stimulated phosphoprotein-like protein (Ena/VASP-like protein) |
| NMD4E_human   | O73599       | ✓       | ✓        | ✓     | Glutamate [NMDA] receptor subunit 4 |
| P73_human     | O15304       | ✓       | ✓        | ✗     | Tumor protein p73 (p53-like transcription factor) (p53-related protein) |
| PSE2_human    | O15162       | ✓       | ✓        | ✓     | Phospholipid scramblase 1 (type II membrane protein) |
| WASF1_human   | Q92558       | ✓       | ✓        | ✓     | Wiskott-Aldrich syndrome protein family member 1 (WASP-family protein member 1) (Verprolin homology domain-containing protein 1) |
| PDE4D1_human  | Q80499       | ✓       | ✓        | ✓     | cAMP-specific 3',5'-cyclic phosphodiesterase 4D |
| Abl1_human    | Q812P0       | ✓       | ✓        | ✗     | Abl-interactor 1 (Abelson interactor 1) (Abl-1) (Spectrin SH3 domain-binding protein 1) (Eps8 SH3 domain-binding protein) (Eps8 binding protein) (eB11) (Nap1 binding protein) (Nap1BP) (Abl binding protein 4) (AblBP4) |
| CAB2L2_mouse  | NP_665850    | ×       | ×        | ×     | Cdk5 and Abl enzyme substrate 2 (interactor with cdk5) (IκB2) |
| ENAH_mouse    | Q03173       | ✓       | ✓        | ✗     | Enabled protein homolog (NPC derived proline-rich protein 1) (NDPP-1) |
| SEMD6A_mouse  | NP_954711    | ×       | ×        | ×     | Semaphorin 6D |
| CRK_human     | P46108       | ✓       | ×        | ✗     | Proto-oncogene C-crk |

The corresponding binding peptides identified by SPMFEP, Scansite, and iSPOT can be found in Table S8.

DOI: 10.1371/journal.pcbi.0020001.t003

DOI: 10.1371/journal.pcbi.0020001.t004
errors due to insufficient sampling of conformational space and/or inaccurate free energy calculation can be cancelled.

There are two major hurdles of applying the VM method in a high-throughput manner. First, the MD simulation and free energy calculations are time-consuming. Second, a domain-peptide complex structure is required. Given the fast pace of advancement of computer power and structural genomics/homology modeling, we believe that the VM method will become more and more useful.

**Materials and Methods**

MD simulations. MD simulations were performed on the 15 binders and the 20 non-binders of the Abl SH3 domain using the AMBER 8 simulation package [19] and AMBER03 force field [40]. The amino acid sequences and the experimentally determined binding affinities of the 15 binders are shown in Table 1 [17]. Ten peptides, B1 to B10, were randomly selected from the human proteome and are considered as non-binders (Table S1). Ten peptides, C1 to C10, do not bind to the Abl SH3 domain but are class I binders of other SH3 domains [12]; C1 and C2 bind to the Src SH3 domains, C3 and C4 bind to the Yes SH3 domain, and C5 to C10 bind to the Grb2 N-terminal SH3 domain (Table S1). We chose the crystal structure of the peptide APSYSPPPWP complexed with the Abl SH3 domain (Class Ibinder and the PDB entry is 1bbz) [25] as the template and mutated it to other peptides using the soap program [41]. The complex was solvated in a rectangular box of about 3,000 TIP3P water molecules so that the boundary of the box is at least 9 Å away from any solute atom. Counter-ions of Na+ were placed based on the Coulomb potential to keep the overall system (the interior plus solvent) neutral. Particle Mesh Ewald (PME) was employed to consider the long-range electrostatic interactions [42]. Following 2,000 steps of minimization, a 1.2 ns (30 ps temperature increase from 10 K to 300 K and 1.17 ns equilibration and data collection) MD simulation with a 2.0 fs time step was performed on each complex. The SHAKE procedure was employed to constrain hydrogen atoms [43] during MD and all heavy atoms of SH3 were restrained using a 5 kcal/mol-Å² harmonic force (see discussion in Supporting Information).

To determine the conformational energy of unbound peptide in solvent, 2.0 ns MD simulation was conducted on each peptide. Each peptide was solvated in a water box of about 1,600 water molecules, which extended 10 Å away from any peptide atom. 1,000 steps of minimization were followed by a 2.0 ns MD simulation for equilibration and data collection using the same settings as described above.

Free energy calculations using the MM/PBSA method. The binding free energy is calculated as:

\[
\Delta G_{\text{bind}} = G_{\text{complex}} - G_{\text{protein}} - G_{\text{guest}} = \Delta G_{\text{MM}} + \Delta G_{\text{Pep}} + \Delta G_{\text{sol}} - T\Delta S
\]

where \(\Delta G_{\text{MM}}\) is the molecular mechanics interaction energy between the SH3 domain and the peptide, \(\Delta G_{\text{sol}}\) and \(\Delta G_{\text{Pep}}\) are the electrostatic and non-polar contributions to desolvation upon peptide binding, respectively, and \(-T\Delta S\) is the conformational entropy change. To consider the conformational flexibility of the peptide, we ran two separate MD simulations on the complex and the free peptide to calculate the binding free energy [16].

\(\Delta G_{\text{MM}}\) was calculated using the sander program in AMBER 8 [19]. \(\Delta G_{\text{Pep}}\) was calculated using the fbsa program in AMBER 8. The grid size used to solve the Poisson-Boltzmann equation was 0.5 Å, and the values of interior dielectric constant and exterior dielectric constant were set to 1 and 80, respectively (the influence of the interior dielectric constant value to the free energy calculation is discussed in Supporting Information). \(\Delta G_{\text{sol}}\) was estimated from the surface area [16, 44]. The peptide-SH3 interaction energies were calculated from 150 snapshots taken from 300 ps to 1.2 ns MD simulation trajectories of the unbound complexes. 160 snapshots taken from 400 ps to 2.0 ns MD simulations on the unbound peptide were used to calculate the conformational energy change for the peptides.

The normal mode analysis was performed to estimate the vibrational component of the entropy using the mode command in AMBER 8 [19]. In the absence of solvent, the structures (complex, SH3, and peptide) were minimized with no cutoff for non-bonded interactions, by using conjugate gradient and then Newton-Raphson minimizations until the root mean square of the elements of gradient vector was less than 5 × 10⁻⁵ kcal/mol. Then, normal mode calculations were carried out with no cutoff for non-bonded interactions. A distance-dependent dielectric constant \(\varepsilon(r) = 4\varepsilon_0\) was used to mimic solvent screening. Frequencies of the vibrational modes were computed at 300K for these minimized structures and using a harmonic approximation of the energies. Due to the high computational demand, only 25 snapshots taken from MD were used to estimate \(-T\Delta S\).

**The VM method.** To investigate the preference of residues at each position, systematic single point mutation was performed on the peptide. The peptide APSYSPPPWP in the crystal structure 1bbz was used as the template. Each residue of the peptide was mutated to the other 19 residues using the soap program [41]. Minimization, MD simulations, and MM/PBSA calculations were performed on all 190 mutated complexes, as well as on the free peptides using the same setup described above. Assuming mutating a single residue of the peptide did not significantly change the peptide configuration, we did not include the conformational entropy in the comparison of 20 residues at each position.

**Single point mutation free energy profile and database scan.** The SPMMFE is a 10 × 20 matrix, which represents the difference between the binding free energies of the mutated peptides and the template peptide APSYSPPPWP (Table 2). SPMMFE can be used as a position specific scoring matrix. The score of each peptide is calculated as:

\[
S_{\text{MMFE}} = \sum_{i=1}^{20} M_{i,6}(S_i, S_e)
\]

where \(M_{i,6}\) is the score of the amino acid \(a\) at the \(i\)th position in the SPMMFE and \(S_i\) is the amino acid at the \(i\)th position of the peptide. All ten-residue-long peptides in the SWISS-PROT database (release 46.4) were scored using the SPMMFE. The Perl script used for the database scan is available upon request.

**Supporting Information**

**Figure S1.** The Correlations between the Experimental and Calculated Relative Binding Free Energies Using an Interior Dielectric Constant of 2

Found at DOI: 10.1371/journal.pcbi.0020001.sg001 (249 KB TIF).

**Figure S2.** The Superposition of 23 Snapshots Extracted from the MD Trajectory from 0.1 ns to 1.2 ns

The structure of SH3 shown here was extracted from the snapshot at 0.1 ns. The residues at P₁, P₉, P₄, P₅, and P₆ of the peptide are colored in red and other residues are colored according to residue type defined in Insight II.

Found at DOI: 10.1371/journal.pcbi.0020001.sg002 (2.9 MB TIF).

**Figure S3.** The Fluctuations of the Free Energy Components

PB represents the polar contribution to the solvation free energy (ΔGPB). Electrostatic means the electrostatic interaction between the peptide and the SH3 domain (ΔEele), and van de Waals means the van de Waals interactions between the peptide and the SH3 domain (ΔEvdw).

Found at DOI: 10.1371/journal.pcbi.0020001.sg003 (358 KB TIF).

**Figure S4.** The Interactions between Peptide FGTYPFPPLLPP and the Abl SH3 Domain

Two residues, Trp36 and Trp57, are shown in stick, and the peptide is shown in ball-and-stick.

Found at DOI: 10.1371/journal.pcbi.0020001.sg004 (942 KB TIF).

**Protocol S1.** The MM/PBSA Calculations Protocols and the Conformational Changes of Ligands in Peptide Binding

Found at DOI: 10.1371/journal.pcbi.0020001.s001 (42 KB DOC).

**Table S1.** The Energetic Components and Binding Affinities for 20 Non-Binders (kcal/mol)

Found at DOI: 10.1371/journal.pcbi.0020001.s001 (66 KB DOC).

**Table S2.** The Energetic Components and Binding Affinities for the 15 Peptide Ligands of the Abl SH3 Domain Using Interior Dielectric Constant of 2 (kcal/mol)

Found at DOI: 10.1371/journal.pcbi.0020001.s002 (558 KB TIF).

**Table S3.** The Binding Free Energies for 20 Peptides Mutated at Position P₅ (kcal/mol)

Found at DOI: 10.1371/journal.pcbi.0020001.s003 (558 KB TIF).

**Table S4.** The Binding Free Energies for 20 Peptides Mutated at Position P₇ (kcal/mol)

Found at DOI: 10.1371/journal.pcbi.0020001.s004 (62 KB DOC).
Table S5. The Binding Free Energies for 20 Peptides Mutated at Position P3 (kcal/mol) | Found at DOI: 10.1371/journal.pcbi.0020001.s005 (61 KB DOC).

Table S6. The Binding Free Energies for 20 Peptides Mutated at Position P2 (kcal/mol) | Found at DOI: 10.1371/journal.pcbi.0020001.s006 (65 KB DOC).

Table S7. The Contribution of Each Residue in Peptide APSYSPPP to the SH3 Binding (kcal/mol) | Found at DOI: 10.1371/journal.pcbi.0020001.s007 (57 KB DOC).

Table S8. The High-Rank Peptides Selected by PMFEP, Scansite, and iSPOT in 13 Abl SH3-Binding Proteins | Found at DOI: 10.1371/journal.pcbi.0020001.s008 (54 KB DOC).

Table S9. The Top 600 Sequences Found in Human Proteins from Database Search | Found at DOI: 10.1371/journal.pcbi.0020001.s009 (643 KB DOC).

Accession Numbers

The Swiss-Prot and TrEMBL (http://www.expasy.org/sprot) accession numbers for the genes and gene products discussed in this paper are:
1. btb9 (1btb9), 1bhz (CA04591), 1ckc (CAA18266), 1gq9 (1gq9a), 1gq9 (1gq9b).

References

1. Russell RB, Alber F, Aloy P, Davis FP, Korkin D, et al. (2004) A structural perspective on protein-protein interactions. Curr Opin Struct Biol 14: 313–324.
2. Lim WA, Richards FM, Fox RO (1994) Structural determinants of peptide-binding HIV protease orientation and of sequence specificity in SH3 domains. Nature 372: 375–379.
3. Feng SB, Chen JK, Yu H, Simon JA, Schreiber SL (1994) Two binding orientations for peptides to the src SH3 domain. Development of a general model for SH3-ligand interactions. Science 266: 1241–1247.
4. Macias MJ, Hyvonen M, Baraldi E, Schultz J, Sudol M, et al. (1996) Structure of the WW domain of a kinase-associated protein complexed with a proline-rich peptide. Nature 382: 646–649.
5. Kurian J, Cowburn D (1997) Modular peptide recognition domains in eukaryotic signaling. Annu Rev Biophys Biomol Struct 26: 259–288.
6. Mahoney NM, Rozwarski DA, Fedorov E, Fedorov AA, Almo SC (1999) Proﬁlin binds proline-rich ligands in two distinct amide backbone orientations. Nat Struct Biol 6: 666–671.
7. Zhou SY (1999) Recognition and regulation of primary-sequence motifs by signaling modular domains. Prog Biophys Mol Biol 71: 359–372.
8. Dalgaro DC, Borstel MC, Ricklejs RJ (1998) SH3 domains and drug design: Ligands, structure, and biological function. Biopolymers 43: 385–400.
9. Cesareni G, Panni S, Nardelli G, Castagnoli L (2002) Can we infer peptide recognition specificity mediated by SH3 domains? FEBS Lett 513: 58–64.
10. Zarrinpar A, Bhattacharyya RP, Lim WA (2003) The structure and function of proline recognition domains. Sci STKE 203: RE8.
11. Rickles RJ, Borstel MC, Zhou XM, Henry PA, Brugge JS, et al. (1995) Phage display selection of ligand residues important for Src homology 3 domain-binding specificity. Proc Natl Acad Sci USA 92: 10999–10913.
12. Sparks AB, Rider JE, Hoffmann NG, Fowlkes DM, Quilliam LA, et al. (1998) Distinct ligand preferences of Src homology 3 domain 3 from Src, Yes, Abl, Cortxin, p53bp2, Pck-g, Grk, and Grb2. Proc Natl Acad Sci USA 95: 1540–1544.
13. Obenguer J, Cantley LC, Vaffe MB (2003) Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res 31: 5653–5661.
14. Bramanti B, Via A, Cestra G, Cesareni G, Helmer Citterich M (2000) SH3-SPOT: An algorithm to predict preferred ligands to different members of the SH3 gene family. J Mol Biol 298: 313–328.
15. Wollack AM, Beschta1 JR (2001) Virtual interaction profiles of proteins. J Mol Biol 313: 317–342.
16. Kollman PA, Nicholls A (1995) Classical electrostatics in biology and chemistry. Structure of the amphiphysin-2 SH3 domain and its role in the prevention of dynamin ring formation. EMBO J 17: 5275–5285.
17. Honig B, Nichols A (1995) Classical electrostatics in biology and chemistry. Science 268: 114–1149.
18. Accelrys (2000) Insight II 2000 User Guide [computer program]. San Diego (California): Accelrys.
19. Wang L, Wang H, Jakalian A, Wang J, Wang JM, et al. (2001) An analysis of the interactions between the Src-SH3 domain and its ligands using molecular dynamics, free energy calculations, and sequence analysis. J Am Chem Soc 123: 3986–3994.
20. Nguyen JT, Turck CW, Cohen FE, Zuckermann RN, Lim WA (1998) Exploiting the basis of proline recognition by SH3 and WW domains: Design of N-substituted inhibitors. Science 292: 2088–2092.
21. Westphal RS, Soderling SH, Abid M, Langeberg LK, Scott JD (2000) Scarb-WAVE-1, a Wiskott-Aldrich syndrome protein, acts as acent-associated multi-kinase scaffolding. FEBS J 19: 4589–4600.
22. Lambrechts A, Kwiatkowski AV, Lanier LM, Bear JE, Vandekerckhove J, et al. (2000) cAMP-dependent protein kinase phosphorylation of EVE: a mena/VASP relative, regulates its interaction with actin and SH3 domains. J Biol Chem 275: 36143–36151.
23. Tofighi T, Zhang H, Kumanogoh A, Takegahara N, Yabuki M, et al. (2004) Guidance of myocardial patterning in cardiac development by Sema3D reverse-signaling. Nat Cell Biol 6: 1294–1301.
24. Bader GD, Betel D, Hogue CWV (2005) BIND: The Biomolecular Interaction Network Database. Nucleic Acids Res 33: 184–205.
25. Zanzoni A, Montecchi-Palazzi L, Quondam M, Ausiello G, Helmer-Citterich M, et al. (2002) MINT: A Molecular INteraction database. FEBS Lett 513: 140–142.
26. Agami R, Blandino G, Oren M, Shaul Y (1999) Interaction of c-Abl and p73 with in vitro-translated ErbB-2, a target for the anti-neoplastic drug pertuzumab. EMBO J 18: 1975–1983.
27. Duan Y, Wu U, Chowdhury S, Lee MC, Xiong G, et al. (2003) A point-charge prediction of Abl SH3 Binding Partners

Acknowledgments

The MD simulations were performed on the Linux cluster in the Center for Theoretical Biological Physics (CTBP) at UCSD. This work has been supported by the National Science Foundation PFC-sponsored Center for Theoretical Biological Physics (grants PHY-0216576 and PHY-0225630). TH is supported by a CTBP postdoctoral scholarship. BL is supported by a National Institutes of Health training grant to the McCammon group (GM131749). WAM is supported by a NIH training grant (5-T32DK07225). We thank Prof. J. Andrew McCammon for providing access to computer software such as Insight II.

Author contributions. TH, KC, and WW conceived and designed the experiments. TH performed the experiments. TH, KC, WAM, and BL analyzed the data. TH and WW wrote the paper.

Competing interests. The authors have declared that no competing interests exist.
force field for molecular mechanics simulations of proteins. J Comput Chem 24: 1999–2012.
41. Xiang Z, Honig B (2001) Extending the accuracy limits of prediction of side-chain conformations. J Mol Biol 311: 421–430.
42. Darden T, York D, Pedersen L (1993) Particle mesh Ewald and N.Log(N) method for Ewald sums in large systems. J Chem Phys 98: 10089–10092.
43. Ryckaert J, Cicotti G, Berendsen HJC (1977) Numerical-integration of cartesian equations of motion of a system with constraints: Molecular-dynamics of n-alkanes. J Comput Phys 23: 327–341.
44. Wang W, Donini O, Reyes CM, Kollman PA (2001) Biomolecular simulations: Recent developments in force fields, simulations of enzyme catalysis, protein-ligand, protein-protein, and protein-nucleic acid non-covalent interactions. Annu Rev Biophys Biomol Struct 30: 211–243.
45. Cicchetti P, Mayer BJ, Thiel G, Baltimore D (1992) Identification of a protein that binds to the SH3 region of abl and is similar to bcr and gap-rho. Science 257: 803–806.
46. Ren R, Mayer BJ, Cicchetti P, Baltimore D (1993) Identification of a 10-amino acid proline-rich SH3 binding site. Science 259: 1157–1161.
47. Glover RT, Angiolieri M, Kelly S, Monaghan DT, Wang JY, et al. (2000) Interaction of the N-methyl-D-aspartic acid receptor NR2D subunit with the c-Abl tyrosine kinase. J Biol Chem 275: 12725–12729.
48. Sun J, Zhao J, Schwartz MA, Wang JY, Wiedmer T, et al. (2001) c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1. J Biol Chem 276: 28984–18990.
49. Beard MB, O’Connell JC, Bolger GB, Houlay MD (1999) The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains. FEBS Lett 22: 173–177.
50. Yamamoto A, Suzuki T, Sakaki Y (2001) Isolation of bNap1BP which interacts with human Nap1 (NCKAP1) whose expression is down-regulated in Alzheimer’s disease. Gene 271: 159–169.
51. Gertler FB, Niebuhr K, Reinhard M, Wehland J, Soriano P (1996) Mena, a relative of VASP and Drosophila enabled, is implicated in the control of microfilament dynamics. Cell 87: 227–239.
52. Donaldson LW, Gish G, Pawson T, Kay LE, Forman-Kay JD (2002) Structure of a regulatory complex involving the Abl SH3 domain, the Crk SH2 domain, and a Crk-derived phosphopeptide. Proc Natl Acad Sci USA. 99: 14053–14058.